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Abstract
The European Committee on Antimicrobial Susceptibility Testing
Subcommittee on Antifungal Susceptibility Testing (EUCAST-
AFST) has determined breakpoints for amphotericin B, itracona-
zole and posaconazole for Aspergillus species. This Technical Note
is based on the EUCAST amphotericin B, itraconazole and posa-
conazole rationale documents (available on the EUCAST website:
http://www.eucast.org/antifungal_susceptibility_testing_afst/ratio
nale_documents_for_antifungals/). The amphotericin B and itr-
aconazole breakpoints are based on epidemiological cut-off
values and clinical experience. The posaconazole breakpoints
are also based on pharmacokinetic and pharmacodynamic data.
Breakpoints will be reviewed regularly or when new data
emerge.
Keywords: Amphotericin B, Aspergillus, breakpoints, EUCAST
Technical Note, itraconazole, posaconazole, susceptibility testing
Original Submission: 23 March 2012; Accepted: 31 March 2012
Editor: E. Roilides
Article published online: 5 April 2012
Clin Microbiol Infect 2012; 18: E248–E250
10.1111/j.1469-0691.2012.03890.x
Corresponding author: M. C. Arendrup, Unit of Mycology, Depart-
ment of Microbiological Surveillance and Research, Statens Serum Insti-
tute, Ørestads Boulevard 5, DK-2300 Copenhagen, Denmark
E-mail: maca@ssi.dk or maiken@arendrup.dk
*EUCAST-AFST: M. C. Arendrup (Chairman, Denmark), W. W. Hope
(Secretary), C. Lass-Flo¨rl, Steering Committee (Austria), M. Cuenca-Estrel-
la, Steering Committee (Spain), S. Arikan (Turkey), F. Barchiesi (Italy), J. Bille
(Switzerland), E. Chryssanthou (Sweden), P. Gaustad (Norway), A. Groll
(Germany), H. Ja¨rv (Estonia), N. Klimko (Russia), O. Lortholary, (France),
C. Moore (UK), A. Velegraki (Greece), and P. Verweij (The Netherlands).
The European Committee on Antimicrobial Susceptibility
Testing Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for amphoteri-
cin B, itraconazole and posaconazole against Aspergillus spe-
cies. This Technical Note is based on the respective
EUCAST rationale documents (available at: http://www.
eucast.org/antifungal_susceptibility_testing_afst/rationale_
documents_for_antifungals/). The rationale documents
include more detail and published references related to the
selection of EUCAST-AFST breakpoints.
Amphotericin B is a polyene antifungal agent with broad-
spectrum activity. A number of different formulations are avail-
able in Europe: amphotericin B deoxycholate (DAmB), liposo-
mal amphotericin B (LAmB), amphotericin B lipid complex
(ABLC), and amphotericin B colloidal dispersion (ABCD).
These compounds have distinct pharmacokinetic and toxicity
profiles. DAmB and LAmB are licensed for first-line treatment
of invasive aspergillosis. ABLC and ABCD are licensed as sec-
ond-line agents. Licensed dosages are as follows: DAmB, 1–
1.5 mg/kg; LAmB, 3–10 mg/kg; ABLC, 3–5 mg/kg; and ABCD,
3–5 mg/kg. The epidemiological cut-off values (ECOFFs) were
established with the use of MIC values from many sources
(Table 1). There are no known resistance mechanisms in
Aspergillus fumigatus that result in reduced susceptibility to
amphotericin B. Multiple clinical studies have suggested that
amphotericin B is active against the wild-type population of
Aspergillus species (with the exception of Aspergillus terreus). A
direct correlation between the MIC of amphotericin B and
clinical outcomes is not possible, because EUCAST methodol-
ogy has not been used; invasive isolates have not been recov-
ered or have not been identified to the species level.
Furthermore, there are no preclinical pharmacokinetic–phar-
macodynamic studies that can be used to support the setting
of breakpoints. Both preclinical and clinical studies suggest that
A. terreus is a poor target for amphotericin B, and can there-
fore be reasonably reported as resistant without further test-
ing [1]. Breakpoints were established with the use of both
microbiological, pharmacokinetic and clinical data.
Itraconazole is a triazole antifungal agent that can be used
for the treatment of both invasive and allergic syndromes
caused by Aspergillus species. Available formulations vary
across Europe, but include capsules and a cyclodextrin sus-
pension that is suitable for both oral and intravenous admin-
istration. The absorption of itraconazole capsules is
increased by food and acidic gastric conditions. The oral sus-
pension has a better oral bioavailability that is not affected
by gastric acidity. The licensed dosage is 200–400 mg/day.
Therapeutic drug monitoring is frequently recommended to
ensure adequate systemic drug exposure [2–6]. ECOFFs
were established with the use of MICs from many sources,
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and are summarized in Table 1. Resistance to azoles has
been detected in A. fumigatus isolates in many European
countries over the last decade [7–12]. Most commonly, the
resistance is linked to point mutations in the target gene
CYP51A. However, other mechanisms may also play a role
[13,14]. The itraconazole MICs for mutant isolates vary
according to the underlying mechanism, but are typically
‡4 mg/L for the most commonly identified mutants [8]. Iso-
lates with reduced susceptibility to itraconazole are fre-
quently cross-resistant to other triazoles, and specific testing
is recommended. Acquired resistance mechanisms within the
other Aspergillus species are poorly understood. However, a
recent study reported itraconazole MIC elevation in an
A. terreus isolate with a CYP51A mutation, suggesting that
species other than A. fumigatus may acquire triazole resis-
tance [15]. Clinical studies suggest that itraconazole is active
against wild-type populations of Aspergillus species. A direct
correlation between the MIC and clinical outcome is not
possible, because clinical isolates are often not identified to
the species level, and susceptibility has not been determined
with EUCAST methodology. There are no preclinical phar-
macokinetic–pharmacodynamic data that can be used to
provide decision support for setting itraconazole break-
points. Breakpoints were established with the use of both
microbiological, pharmacokinetic and clinical data.
Posaconazole is a broad-spectrum triazole antifungal agent
approved for refractory or second-line invasive fungal dis-
eases (including aspergillosis) and for prophylaxis of invasive
fungal infections in immunocompromised patients. The
licensed regimens for the prophylaxis and treatment of inva-
sive disease are 200 mg every 8 h and 400 mg every 12 h,
respectively. Oral bioavailability is highly variable. Therapeutic
drug monitoring is increasingly recommended, although
definitive targets are not known. Trough concentrations of
0.7 and 1 mg/L are reasonable for the prophylaxis and treat-
ment of established disease, respectively [5,16,17]. The EC-
OFFs were established by the use of MIC values from many
sources (Table 1). Reduced susceptibility to posaconazole is
associated with mutations in CYP51A [8–12]. The MICs of
CYP51A mutants are mechanism-dependent, but are typically
‡0.25 mg/L [8]. The MIC distribution of CYP51A mutants
overlaps with that of the wild-type population, which is prob-
lematic for the setting of breakpoints [12]. Infections caused
by these isolates should not be treated with posaconazole
unless specific clinical evidence becomes available suggesting
that such an approach is effective. Isolates resistant to posa-
conazole but susceptible to itraconazole are extremely rare.
Therefore, itraconazole susceptibility testing may be helpful
as an initial screening marker for the detection of multi-azole
resistance. A direct correlation between MIC and clinical
outcomes is not possible, because the relevant studies have
not been performed. Near-maximal antifungal efficacy for po-
saconazole salvage therapy of invasive aspergillosis is
observed with mean serum concentrations of c. 1.25 mg/L
[18]. Pharmacodynamic targets can only be achieved for the
entire wild-type population if adequate systemic drug expo-
sure is confirmed with the use of therapeutic drug monitor-
ing [19,20]. Because of overlapping MIC distributions for the
wild-type and mutant populations, and because of the unac-
ceptably low target attainment rates for isolates at the upper
end of the wild-type population, the breakpoints are set one
step lower than the ECOFF. This is a conservative decision,
and will be revised if specific clinical and/or pharmaco-
dynamic data arise suggesting that isolates currently classified
TABLE 1. Aspergillus species-specific amphotericin B, itraconazole and posaconazole EUCAST epidemiological cut-off values
(ECOFFs) and breakpoints
Speciesa
Species-related breakpointsb (mg/L)
Amphotericin B Itraconazole Posaconazolec
ECOFF Breakpoint ECOFF Breakpoint ECOFF Breakpoint
A. flavus 4 IEd IEd 1 S £ 1 R > 2 0.5 IEd IEd
A. fumigatus 1 S £ 1 R > 2 1 S £ 1 R > 2 0.25 S £ 0.12 R > 0.25
A. nidulans ND Notee Notee 1 S £ 1 R > 2 0.5 IEd IEd
A. niger 1 S £ 1 R > 2 4 IEd IEd 0.5 IEd IEd
A. terreus 4 – – 1 S £ 1 R > 2 0.25 Notee Notee
A. versicolor ND ND ND ND IEd IEd ND Nd ND
IE, insufficient evidence; ND, not determined, owing to insufficient data.
‘–’ indicates that susceptibility testing is not recommended, as the species is a poor target for therapy with the drug. Isolates may be reported as R without prior testing.
aThere is insufficient evidence to set non-species-related breakpoints.
bIn order to simplify the EUCAST tables, the intermediate category is not listed. It is readily interpreted as the value between the S and the R breakpoints. For example, for
MIC breakpoints listed as S £ 1 and R > 2, the intermediate category is 2 (technically >1–2). There is insufficient clinical evidence to set breakpoints for species other than
those listed.
cProvided that adequate drug exposure has been confirmed by the use of therapeutic drug monitoring.
dThe MIC values are, in general, higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown. There is insufficient evidence to set
breakpoints for these species.
eThere is inadequate clinical information on the clinical outcome for patients infected with wild-type strains, although the MIC distributions are similar to those for A. fumiga-
tus.
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as ‘I’ or ‘R’ can be safely treated with posaconazole. Break-
points were established by the use of microbiological, clinical
and pharmacokinetic–pharmacodynamic data.
EUCAST breakpoints only apply to licensed regimens. The
breakpoints will be reviewed when more data are available for
Aspergillus species that were not assigned breakpoints during
the present review, when there are clinical data for isolates
with MIC values outside the wild-type distribution, or when
there are further data related to optimal drug exposures.
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